Immatics, a Tuebingen, Germany-based cancer immunotherapy company, closed a $58m Series E financing round.
Backers included dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and Amgen.
The company intends to use the funds to continue to advance its candidates.
Led by Peter Chambré, Chairman, Immatics is advancing its pipeline of adoptive cell therapies in a series of clinical trials. This will include the candidates:
IMA101, an ACTolog® endogenous T-cell therapy pioneered by Professor Cassian Yee, M.D. and
IMA201, an ACTengine® approach, based on transducing a patient’s own T-cells to express a tumor-specific exogenous T-cell receptor (TCR) and redirecting activated T-cells to the tumor sites.
The company is also developing a pipeline of bispecific TCR candidates, with the aim to redirect and activate the T-cell response towards cancer cells expressing specific tumor targets and validating novel tumor targets for cancer immunotherapy, using its XPRESIDENT® technology.